Yearly Archive

Yearly Archives: 2014

January 3, 2014 no comments

Never mind how many, feel the sales potential – the Class of 2013 FDA Approvals

With thirty-nine approvals from the FDA, 2012 triggered a wave of optimism in the pharmaceutical industry.  But if 2012 was characterized by an increased number of approvals, the sales potential of many of those new products was underwhelming.  For 2013, the number of approvals may have gone down, but the quality (in terms of clinical impact and sales potential) has increased dramatically.


Twenty-seven approvals (twenty four of them drugs) in 2013 may be twelve less than the 2012 haul, but it is still above average across the last two decades.  And in any case, the number of approvals is a poor surrogate for the productivity of the industry.


With between five and seven products headed for blockbuster status, and Sovaldi™ potentially reaching peak sales in excess of $10billion annually, the output from the global pharmaceutical industry in 2013 shows signs of return to the glory days of the late 1990s.  Indeed, arguably, 2013 may be the best year ever in terms of future sales potential for newly-approved products.  Predicted global sales of these medicines five years after launch dwarf the equivalent figure for the class of 2012 by as much as 10-fold.  With this kind of R&D productivity, things look rosier for the global pharmaceutical industry than they have done for more than a decade.



June 24, 2013 no comments

Positive publication bias IS harmful

DrugBaron was intrigued to see a paper published …

June 11, 2013 no comments

Soriot and AstraZeneca face increasing headwinds: can the acquisitions of Omthera and Pearl boost the engine?

The acquisition of Pearl Therapeutics for up to …

January 7, 2013 no comments

The 39 (mostly small) Steps: The Class of 2012 FDA Approvals

The pharmaceutical industry achieved 39 approvals in 2012 …

October 29, 2012 no comments

Bardoxolone and BG-12: A Tale of Two CITIEs (Covalently-Interacting Therapeutic IntErventions!)

Until 18th October, bardoxolone methyl (Abbott/Reata) and BG-12 …

August 8, 2012 2 responses

“Idea Bubbles”: The dangers of big theories in low-validity environments

This week, Pfizer and J&J finally discontinued development …

June 19, 2012 no comments

The mirage of “big data” in clinical trials

It is inevitable that clinical trials will fail.  …

September 4, 2011 no comments

Crestor™ versus Lipitor™: King Canute Fails to Stem the Tide

As high stakes battles go, the 20-year competition …

August 30, 2011 comments

Apixaban and Prasugrel: Blockbusters or White Elephants?

A new study suggests that factor Xa inhibitors, …


Yearly Archive